Some people with the gene did not have expected outcomes if they were heavy meat-eaters ...

In the brain, Alzheimer’s is characterized by two proteins, amyloid beta and tau, that become dysfunctional, forming plaques ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Older people with a genetic risk of Alzheimer's disease did not experience the expected increase in cognitive decline and dementia risk if they consumed relatively large amounts of meat.

What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

The findings could help clinicians use neuropsychiatric symptoms to prepare patients and families for a type of dementia ...

Research roundtable highlights early detection, biomarkers, interventions ...

Guest columnist Melissa Zapanta Shelton is executive director of the Alzheimer’s Association Cleveland and Greater East Ohio chapters. Currently, 55 million people are living with Alzheimer’s disease ...

The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for cognition or function in patients with early Alzheimer’s.

Researchers say they have developed a blood test that can help predict the start of Alzheimer's disease symptoms, allowing them to receive a diagnosis.